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A Prototype Antifungal Contact Lens
Joseph B. Ciolino,1,2 Sarah P. Hudson,3,4 Ashley N. Mobbs,3 Todd R. Hoare,3,5
Naomi G. Iwata,3,6 Gerald R. Fink,7 and Daniel S. Kohane2
PURPOSE. To design a contact lens to treat and prevent fungal
ocular infections.
METHODS. Curved contact lenses were created by encapsulating
econazole-impregnated poly(lactic-co-glycolic) acid (PLGA)
films in poly(hydroxyethyl methacrylate) (pHEMA) by ultravi-
olet photopolymerization. Release studies were conducted in
phosphate-buffered saline at 37°C with continuous shaking.
The contact lenses and their release media were tested in an
antifungal assay against Candida albicans. Cross sections of
the pre- and postrelease contact lenses were characterized by
scanning electron microscopy and by Raman spectroscopy.
RESULTS. Econazole-eluting contact lenses provided extended
antifungal activity against Candida albicans fungi. Fungicidal
activity varied in duration and effectiveness depending on the
mass of the econazole-PLGA film encapsulated in the contact
lens.
CONCLUSIONS. An econazole-eluting contact lens could be used
as a treatment for fungal ocular infections. (Invest Ophthalmol
Vis Sci. 2011;52:6286–6291) DOI:10.1167/iovs.10-6935
Fungi are a leading cause of ocular infection in tropical andsubtropical climates, which cover much of the developing
world,1,2 and also in temperate climes.2,3 The prevalence of
fungal keratitis continues to increase in industrialized coun-
tries, particularly after trauma or surgery.4 Topical ophthalmic
solutions, or eye drops, are the most common treatment for
fungal keratitis, but 15% to 27% of patients require surgical
intervention.5 The failures of topical antimycotic treatments
may be related to the limitations of eye drops as a form of drug
delivery. Eye drops generate a transiently high concentration
on application followed by a short period of effective thera-
peutic concentration and then a prolonged period of under-
dose. Furthermore, each drop is diluted and washed away by
reflex tearing and dispersed by blinking. As a consequence,
only 1% to 7% of drug in a drop is absorbed into the eye.6 The
cornea absorbs only a fraction of this dose, in part due to the
tissue’s short contact time with the topical drops.7
Other factors prevent antifungal drops from reaching fun-
gicidal levels in the cornea. At low concentrations, the drugs
may be fungistatic, stopping proliferation of the organisms
within the tissue. However, to kill fungi, higher drug concen-
trations are necessary.8 Furthermore, many drugs have diffi-
culty penetrating the corneal epithelium.9–11 The barrier effect
can be overcome with higher drug concentrations and pro-
longed contact time with the tissue.10 Consequently, patients
with fungal keratitis frequently need to self-administer antifun-
gal drops every hour12,13—initially day and night.11 If the
treatment regimen is effective, the drop frequency is reduced,
but the regimen persists for weeks to months.11 Not surpris-
ingly, compliance can be problematic, both acutely and over
long periods. A sustained-release system for ophthalmic drugs,
including antifungals, could improve compliance and treat-
ment efficacy.
The concept of delivering drugs specifically through a con-
tact lens was introduced as early as 1960.14 Several researchers
designed contact lenses for drug delivery,15,16 but no products
are currently commercially available. Recently, we have de-
scribed a contact lens composed of a drug-loaded polymer film
contained within poly(2-hydroxyethyl methacrylate) (pHEMA),
a polymer commonly used in the manufacture of contact
lenses.17 With a flat prototype contact lens, a near zero-order
release of relatively large quantities of drug was achieved over
at least 30 days for both the fluorescent indicator sodium
fluorescein and the antibiotic ciprofloxacin.17
Here, we describe the formulation and characterization of a
contact lens designed for extended release of an antifungal
drug, econazole. Econazole was chosen for its broad-spectrum
antifungal activity,18 low cost, and wide availability in the
developing world. It has been shown to be effective in the
treatment of fungal keratitis.8 Poly(lactic-co-glycolic) acid
(PLGA) was used to fabricate the econazole-polymer films en-
capsulated inside the contact lenses. PLGA is well-known for its
biocompatibility, biodegradability, and ability to control drug-
release kinetics.19–22
MATERIALS AND METHODS
High-molecular-mass (118 kDa) PLGA (65:35; 65% lactic acid and 35%
glycolic acid) was obtained from Lakeshore Biomaterials (Birmingham,
AL). A photoinitiator (Irgacure 2959) was purchased from Ciba Spe-
cialty Chemicals Corporation (Tarrytown, NY). Econazole powder,
2-hydroxyethyl methacrylate (HEMA), ethylene glycol dimethacrylate
(EGDMA), glucose, histidine, leucine, and all the other reagents were
purchased from Sigma-Aldrich (St. Louis, MO). Candida albicans
strain SC5314 was regrown from frozen stocks from the Whitehead
Institute (Boston, MA). Phosphate-buffered saline (PBS, pH 7.4) was
obtained from Invitrogen (Carlsbad, CA). Yeast nitrogen base (YNB)
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and yeast extract peptone (YEP) media from DIFCO (BD Biosciences,
Franklin Lakes, NJ) were used.
Solvent-Casting of Drug-Polymer Films
To create the drug-polymer film, 100 mg of PLGA was dissolved in 4 mL
of ethyl acetate. Econazole (200 mg) was added to the solution and
vortexed to form a fine suspension, which was poured into a Teflon
well. Ethyl acetate was removed by evaporation in a fume hood with
laminar air flow overnight. The resulting films were then lyophilized
for 48 hours. Films with three different surface areas (12.8, 55.4, and
180 mm2) were punched out of the econazole-PLGA film. PLGA-only
films, created using the same process, using 100 mg of PLGA and 4 mL
of ethyl acetate, but lacking econazole, served as the control.
Coating the Drug-Polymer Film in pHEMA
All films were coated with pHEMA by ultraviolet (UV) photopolymer-
ization.17 A HEMA solution was mixed and degassed as previously
described.17 The solution was then transferred into a contact lens mold
(14 mm in diameter and 150 m in height) and placed in a nitrogen
atmosphere. The monomer solution was polymerized with a 305-nm
UV lamp over 60 minutes to form the bottom pHEMA layer of the
composite contact lens. The dried pHEMA gel was then transferred
into a deeper contact lens mold (14 mm in diameter and 500 m in
height). After the drug-PLGA film and PLGA film (control) were man-
ually pressed onto the dried pHEMA gel, an additional 150 L of the
monomer/photoinitiator solution was added to the mold and UV-
photopolymerized under the same conditions. The resulting contact
lens prototype consisted of a thin drug-PLGA film encapsulated on all
sides with pHEMA. Each lens was assigned a code PLGAx, where xwas
the total number of milligrams of econazole contained within the
contact lens (Table 1).
Econazole Antifungal Assay
Growth of C. albicans. C. albicans strain SC5314 was regrown
from frozen stocks from the Whitehead Institute. In all cases, C.
albicans was maintained on YEP-agar plates. For experiments, liquid
YEP (50 mL) was inoculated with one colony overnight. After that
time, the suspension was centrifuged (5 minutes at 8000g), the super-
natant was discarded, and the cells were washed twice with PBS (pH
7.2; 50 mL). The cells were counted on a hemocytometer and diluted
to 0.5 to 1 107 or 2 to 4 107 cells/mL in YNB medium with 50 mM
glucose.
Fungicidal Effect of Econazole. To test the fungicidal effect
of econazole, the drug was suspended in 225 L of YNB medium over
a range of concentrations (0–1 mg/mL). An additional 75 L of fresh
YNB containing 2 to 4  107 cells/mL C. albicans SC5314 was subse-
quently added. After 2 hours, the suspension was diluted by a factor of
1000, 200 L of the diluted suspension was plated onto YEP agar plates
and incubated at 37°C for 24 hours, after which the viable colonies
were counted. The fungicidal effect of econazole against C. albicans
was assessed in duplicate.
Fungicidal Effect of Direct Exposure to the Contact
Lenses. To test the effect of directly exposing the contact lenses to
fungi, we immersed the contact lenses in 1 mL of YNB medium with 50
mM glucose and incubated them at 37°C, with shaking at 100 rpm. The
YNB medium was replaced every 24 hours with fresh medium. At
predetermined intervals, the contact lenses were removed, irrigated
with YNB medium, and placed in the wells of a 24-well tissue culture
plate with 1 mL of the Candida suspension (0.5–1 107 cells in YNB).
The lenses were incubated for 2 hours at 37°C, with shaking at 100
rpm. The contact lenses were subsequently removed, placed in fresh
YNB medium with 50 mM glucose, and incubated at 37°C, with
100-rpm shaking. The remaining medium was vigorously stirred and
subsequently diluted by a factor of 1000. Next, 200 L of the diluted
medium was plated on YEP agar plates. The YEP plates were incubated
at 37°C for 24 hours, and yeast colonies were counted on both the
contact lens–exposed samples and a yeast-only control. The fungicidal
activity, as calculated here, is in part a result of the experimental design
(e.g., starting fungal cell counts). We cannot exclude the possibility
that fungal cell killing may have been less than 100% in some samples
if cells had been seeded at higher concentrations.
Fungicidal Effect of Drug Release. To assess the fungicidal
effect of the econazole-releasing contact lenses, the lenses were im-
mersed in 1 mL of YNB medium with 50 mM glucose, shaken at 100
rpm, and incubated at 37°C. This is the standard temperature for the
purpose of testing the extraction from materials and medical devices,
including contact lenses.23–25 Previous studies demonstrated no signif-
icant difference between the growth of C. albicans at 37°C and
35°C,26 which has been found to be the surface temperature of the
cornea with the lids open.27,28 After this incubation, the medium was
removed completely, and the contact lenses were immersed in fresh
medium every 24 hours. YNB drug release medium (225 L) was
collected at each time point and subsequently diluted with 75 L of
fresh YNB containing 2 to 4  107 cells/mL C. albicans SC5314. After
2 hours, the suspension was diluted by a factor of 1000, plated onto
YEP agar plates, and incubated at 37°C for 24 hours, after which viable
colonies were counted in the same manner as above. When the YEP
recovery plates were examined and the colonies counted after 24
hours (3–4 days), the colony counts remained unchanged beyond the
24-hour period. Therefore, we report the growth after 24 hours of
growth. Control samples were prepared by adding 75 L of YNB
containing 2 to 4 107 cells/mL C. albicans SC5314 to 225 L of YNB.
TABLE 1. Morphology, Dimensions, and Amount of Econazole Contained within Each Type of
PLGA Film
Film Label PLGA16 PLGA4 PLGA1
Morphology
Outer diameter, mm 15.9 13.7 11.1
Inner diameter, mm 4.7 9.5 9.5
Surface area, mm2 180.0 55.5 12.8
Econazole, mg/film 15.5 3.6 0.9
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Effect of Freeze-Drying on the Fungicidal Effect of
Contact Lenses. A preliminary test was conducted to ascertain the effect
of freeze drying on the econazole-loaded contact lenses. A pair of contact
lenses containing an econazole-PLGA film (PLGA16) was quick frozen with
liquid nitrogen and lyophilized for 24 hours. The freeze-dried lenses were
subsequently tested for the fungicidal effects associated with direct exposure
to the contact lenses, as described above.
Scanning Electron Microscopy
Antifungal contact lenses containing an econazole-PLGA film (PLGA16)
were immersed in 1 mL of PBS at 37°C, shaking at 100 rpm. The
medium was changed every 24 hours for 10 days. The contact lenses
were imaged before and after drug release. The dry lenses were
cross-sectioned with a microtome and sputter coated with a gold-
plutonium alloy under vacuum (Hummer 6.2; Anatech Limited, Union
City, CA). Images were acquired with a scanning electron microscope
(JSM 5600 LV; JEOL USA. Inc, Peabody, MA).
Raman Spectroscopy
Econazole, a microtome cross-sectioned dry HEMA gel (lacking an
econazole-PLGA film), and microtome cross-sectioned lenses (contain-
ing an econazole-PLGA film, PLGA16) were placed in a Raman spec-
trometer with microprobe (Hololab 5000R; Kaiser Optical Systems,
Inc., Ann Arbor, MI). Raman spectroscopy measurements were per-
formed with a 28-mW solid-state laser (785 nm) with a 100-m fiber, a
10 objective, and an acquisition time of 120 seconds. For the cross-
sectioned lenses, the laser spot was centered in the middle of the
drug-polymer film.
RESULTS
Drug-PLGA Films
The econazole-PLGA film was produced through solvent cast-
ing, then punched and/or cut into various shapes (Table 1),
and lyophilized to remove residual ethyl acetate. After lyophi-
lization, the films measured 150 m in thickness. Of note, the
flexibility of the films (with and without econazole) decreased
substantially after lyophilization due to the elimination of re-
sidual ethyl acetate.
pHEMA Coating Using Composite Construction
Econazole-PLGA films and PLGA-only films were encapsulated
inside a hydrogel layer as previously described.17 The final
contact lens measured 14 mm in diameter and 450 m in
thickness in its dry state. After hydration, the prototype contact
lens demonstrated the flexibility typical of soft contact lenses
and measured 15.5 mm in diameter, representing an increase
of approximately 10% from its dehydrated state. The base
curve (radius of an imaginary sphere with the curvature of the
back of the contact lens) was 8.05 mm. The central lens
remained free of the drug-polymer film after pHEMA encapsu-
lation (Fig. 1, Table 1).
Antifungal Activity
We have developed antifungal devices that can kill fungi by
releasing fungicidal activity into surrounding media and/or by
direct contact between the antifungal surface and yeast.29,30
The capacity of released econazole to effectively kill fungi was
verified by incubating econazole-loaded contact lenses in YNB
fungal medium for predetermined time intervals, at which
points the lenses were removed, and the release media were
tested for fungicidal activity after 24 hours of growth.
Econazole released from the lenses effectively killed fungi
over an extended period (Fig. 2). Release medium from contact
lenses containing 16 mg of econazole (PLGA16) killed 100% of
fungi for 21 days. Release medium from lenses containing
lower amounts of econazole were less efficacious and killed for
shorter periods.
Previously, we have shown that hydrogels containing am-
photericin B have the desirable property of killing fungi rapidly
(i.e., complete killing within 2 hours), and can maintain that
level of fungicidal activity over long periods.29,30 To determine
whether the drug-eluting contact lens could do the same,
lenses were placed in medium containing 1 mL of the Candida
suspension (0.5–1  107 cells in YNB) for 2-hour periods at
predetermined intervals (Fig. 3). The fungi were completely
killed by exposing fungal suspensions directly to PLGA16 con-
tact lenses up to 8 to 10 days after the beginning of the drug
release process. Lenses with lower econazole loadings killed
lower percentages of fungi over approximately the same pe-
riod, whereas the control lens had no impact on fungal viability
and became overgrown within 2 days.
Long-term storage of such lenses could require lyophilization
to prevent drug elution and/or degradation of the biodegradable
FIGURE 1. Left: Photograph of prototype contact lens containing an
econazole-PLGA film with a surface area of 180 mm2. Note the clear
optical axis. Right: schematic of prototype antifungal contact lens.
FIGURE 2. Antifungal activity of YNB media containing econazole
eluted from drug-containing contact lenses. Data are the mean 
SD. n  4.
FIGURE 3. C. albicans killed by direct exposure to the econazole-
containing contact lenses. Data are the mean  SD. n  4.
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component (if any). To address the effect of such storage, the
fungicidal activity of the optimally effective PLGA16 contact lens
was assessed after 24 hours of lyophilization (Fig. 3). The lyoph-
ilized PLGA16 lens exhibited fungicidal activity similar to that of
the nonlyophilized lens, although the duration of antifungal activ-
ity was 1 to 2 days shorter for the lyophilized lens.
Lens Characterization before and after
Drug Release
Contact lenses were imaged before and after 10 days of drug
release (Fig. 4). When imaged by scanning electron microscopy
(SEM), the econazole-PLGA layer appeared as a structurally heter-
ogeneous layer sandwiched between the homogeneous layers of
lens hydrogel. After 10 days of drug release, the econazole-PLGA
layer contained some small pores and appeared substantially de-
pleted, thinner, and more homogeneous. The SEM images were
consistent with the gross appearance of the embedded films in
the contact lenses, which appeared significantly less opaque after
releasing econazole for 10 days.
To ascertain whether any drug was left in the lenses after 10
days of drug release, Raman spectroscopy was performed on
cross-sectioned contact lenses before and after release. A con-
tact lens containing the econazole-PLGA film (before release)
demonstrated spectral peaks seen in crystalline econazole
(3073, 3061, and 2964 cm1) and cross-linked HEMA (2941
and 2884 cm1; Fig. 5, top). After 10 days of drug release, the
HEMA peaks (2941 and 2884 cm1) were still present, but the
spectral peaks characteristic of econazole were no longer
clearly observed when viewing the Raman shift from 0 to 3300
cm1. However, on zoom, several minor peaks (423, 391, and
244 cm1) indicative of econazole were demonstrated on the
contact lens after 10 days of release (Fig. 5, bottom), and this
may account for the fungicidal effect observed beyond 10 days
(Figs. 2, 3).
DISCUSSION
We have produced a curved antifungal contact lens with the
ability to kill fungi for at least 3 weeks (Fig. 2). The efficacy and
duration of the killing was dependent on the drug loading of
the contact lens. Econazole, the drug released in this study, is
U. S. Food and Drug Administration (FDA)–approved for topi-
FIGURE 4. Scanning electron and
photomicrographs of econazole-
PLGA films within pHEMA hydrogels
before and after 10 days of drug re-
lease. Magnification: top left, 190;
top right, 430 magnification.
FIGURE 5. Raman spectra of econazole, a pHEMA film, a PLGA film, and a
contact lens containing an econazole-PLGA film (PLGA16) before and after 10
days of drug release. Top: shift from 0 to 3300 cm1. Zoom of the Raman
spectra (bottom, 180–550 cm1) demonstrated multiple peaks (423, 391,
and 244 cm1) in the contact lens that were indicative of econazole.
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cal use in the treatment of skin infections, but has not been
approved for ophthalmic use. In the United States, there is only
one drug (natamycin 5%) that is FDA approved for topical
ophthalmic use to treat fungal ocular infections.31,32 From a
survey of American ophthalmologists, half would prefer to use
more than one medication as a first-line treatment, and most
would use a different antifungal than natamycin for mono-
therapy, if the various antifungals were readily available.32
Econazole is commonly used in the developing world and in
the United Kingdom.33 We chose it because of its low cost,
wide availability in the developing world, and broad-spectrum
antifungal properties.18 It is effective at killing both filamen-
tous fungi and molds. Comparative minimum inhibitory con-
centration (MIC) and in vivo data suggest that C. albicans is
more difficult to kill than Fusarium when treating with eco-
nazole.34 Therefore, since this device is effective at killing C.
albicans, then it should also kill Fusarium, which has a lower
MIC for econazole. Azole antifungal drugs have been used as
adjunctive therapies for amebic keratitis; it is conceivable that
they could play the same role via a drug-eluting lens.
PLGA, the polymer used here, has been widely studied and
FDA approved for ocular use.19–22 Using a similar contact lens
design (drug-polymer film encapsulated in HEMA hydrogel),
we have previously demonstrated that the rate of drug release
could be altered by either changing the molecular weight of
the PLGA or by changing the proportion of PLGA to drug
within the film.17 Based on these observations, it is likely that
the duration of fungicidal action could have been lengthened
by using a PLGA with a higher molecular mass or by increasing
the ratio of PLGA to drug within the film.
The curved nature of the lens studied here is an advance
over our previously reported proof-of-principle prototype
drug-eluting lens.17 Both the curvature (8.05 mm base curve)
and the diameter (15.5 mm) are consistent with measurements
of commercially available lenses.
Storage of drug-eluting lenses could be problematic if in the
wet state, particularly if the drug-containing polymer were
biodegradable, as it was here. Lyophilization, or freeze drying,
is therefore an attractive potential means of storage.35 Lyoph-
ilization did not have an appreciable effect on the ability of the
lenses to kill fungi.
An econazole-eluting contact lens would expand ophthalmol-
ogists’ armamentarium for treating fungal keratitis, which can be
difficult to diagnose and to treat. Because fungus may not grow
from cultures for up to 14 days, ophthalmologists often initiate
treatment based on the clinical scenario and the cornea ulcer’s
appearance. An inadequate treatment response could be due to
several factors that include an inaccurate fungal diagnosis or poor
patient compliance. Therefore, poor patient compliance can com-
plicate the ophthalmologist’s treatment decision-making process.
In the case of fungal keratitis, compliance is particularly difficult
because of the taxing nature of the treatment regimen, which
initially includes hourly drop administration throughout the night.
For the patients who are compliant, the lack of sleep adds to the
stress of this potentially blinding condition.
A potential concern is whether sustained elution of econa-
zole or any other antifungal agent would lead to more rapid
selection of resistant forms. Although this matter deserves
close study, it seems unlikely that the development of resis-
tance would be a greater issue than is the case with the
alternative, which is eye drops.
A drug-eluting contact lens may entail considerations relat-
ing to lens care. These considerations are minimized if the lens
is worn continuously. Similar to a bandage contact lens, a
fungicidal contact lens could be inserted by an ophthalmolo-
gist and left in place until it is removed and/or replaced by the
physician. However, it is important to understand that if the
lens is removed by the patient, it will continue to release drug,
and any biodegradable components will continue to degrade,
albeit at a slower rate if stored at room temperature. The
release would continue until some equilibrium was reached
with the drug in the storage solution. In the case of an anti-
fungal contact lens, release while in storage could be helpful in
preventing fungal keratitis, which has been identified as a
problem with lens care.36
Based on this study, an econazole-eluting contact lens could
effectively kill Candida for weeks at a time using an HEMA
hydrogel. The hydrogel materials used here were model com-
pounds used for proof-of-concept. It may be possible to use
other hydrogel materials, such as a silicone-based hydrogel
which is more oxygen-permeable and may be a better candi-
date for a continuous-wear contact lens. However, it is possible
that the design or specific elements of the production process
would have to be modified to accommodate a change in the
hydrogel material, or that some materials would not be ame-
nable to formulation in the manner described here. Therefore,
additional testing would be necessary to determine the feasi-
bility of incorporating a silicone hydrogel into this design.
When developing a medical device for clinical use, it is
important to consider the regulatory path that the product
must travel. In the United States, a drug-releasing contact lens
may be regulated by the FDA as a combination drug device,
since it contains more than one regulated component.37 The
primary mode of action of the lens would be determined by the
FDA who would then assign the lead center (drug or device)
based on this decision.37 Fungal keratitis would likely be the
treatment indication for an econazole-releasing contact lens.
In the industrialized world, an antifungal contact lens could
improve the treatment of mycotic eye infections by reducing
the treatment burden and by increasing patient compliance.
However, warm, humid areas of the developing world may
most benefit from this device, since the inhabitants of those
regions experience a high prevalence of mycotic eye infec-
tions.1,32,38,39 Because of trachoma and other diseases, they
also have a high rate of cornea blindness, but ophthalmologists
have been reluctant to use a keratoprosthesis in this patient
population because of the fear of fungal endophthalmitis. In
such areas, econazole-releasing contact lenses may not only
improve the treatment of mycotic eye infections, but they may
also expand the surgical options to include keratoprosthesis
and other forms of ocular reconstruction.
CONCLUSION
We have designed a curved, econazole-releasing contact lens
that consists of a econazole-PLGA film encapsulated within a
pHEMA hydrogel. The contact lenses retained their fungicidal
effects over the course of 3 weeks. Such lenses may offer an
alternative treatment of fungal keratitis and may also represent
a platform for ocular drug delivery with applications beyond
infectious eye diseases.
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